Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABLE: Cerebralcare Pills for Cerebral Small Vessel Disease
NCT05578521Phase 4Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of yangyintongnao in Cerebral Small Vessel Disease (CSVD) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Progression in cognition function (Montreal Cognitive Assessment) at 6 months. Status: unknown.
02
Drugs
yangyintongnao
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NCT05578521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578521.